News - Pfizer, Nephrology and Hepatology


Popular Filters

Pfizer's Torisel fails in Ph III advanced renal cell cancer study


There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III…

BayerNephrology and HepatologyNexavarOncologyPfizerPharmaceuticalResearchTorisel

Robust growth forecast for renal cell carcinoma market


The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

Back to top